Bladder Cancer Drug Pipeline Analysis Report 2025
Description
According to the World Health Organization, bladder cancer is the 9th most common cancer globally. Statistics say that in 2022, approximately 600,0 00 people were diagnosed with bladder cancer and around 220,000 deaths were encountered with the condition. Several companies are conducting clinical trials for their drugs intended to combat bladder cancer. Such initiatives indicate a promising future for bladder cancer treatment in the coming years.
Report Coverage
Bladder Cancer Report by Expert Market Research gives comprehensive insights on the bladder cancer drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The report includes an analysis of over 100 pipeline drugs and 50+ companies . Moreover, the bladder cancer pipeline analysis based on efficacy and safety measures outcomes published for the trials will be covered including their adverse effects in bladder cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing bladder cancer pipeline development activities are covered. Additionally, bladder cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Bladder Cancer Drug Pipeline Outlook
Bladder cancer occurs when there is an uncontrollable growth of cells in the bladder lining. Initially these cancerous cells affect the normal functions of bladder and later spread to surrounding areas. Bladder cancer is of two types – non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Non-muscle-invasive bladder cancer is considered early stage and represents about 70-75% of all diagnoses while muscle-invasive bladder cancer is considered as an advanced stage and represents 25-30% of diagnoses. Bladder cancer is the fourth most common cancer in men.
The symptoms of bladder cancer include blood in the urine (hematuria), which may lead to bright red urine, painful and frequent urge to urinate, as well as back pain among others. The bladder cancer treatment options for bladder cancer depend on factors such as the grade and stage of the cancer. It includes chemotherapy in the bladder, chemotherapy for the whole body, immunotherapy , targeted therapy, radiation therapy and surgery. The approaches for bladder cancer surgery include transurethral resection of bladder tumor (TURBT), cystectomy, neobladder reconstruction, and continent urinary reservoir among others.
The ongoing research on clinical trials aims to identify efficient therapeutic targets, development of novel therapies which are emerging as promising treatment alternatives for bladder cancer.
For instance, in 2023, the U.S. FDA approved a two-drug combination of pembrolizumab (EV/pemb ro) and enfortumab vedotin to treat metastatic urothelial bladder cancer. The results of clinical trial showed that EV/pembro was better than cisplatin-based combination chemotherapy as first-line treatment. The study results also highlighted a reduction of 55% in disease progression compared to cisplatin-based chemotherapy treatment.
Mayo Clinic is conducting another trial for a bladder cancer emerging drug and is under phase III. The study is being conducted to assess the efficacy of immunotherapy for treatment-resistant non-muscle-invasive bladder cancer.
The bladder cancer report assessment covers the pathophysiology and epidemiology of bladder cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for the treatment of bladder cancer in detail.
Bladder Cancer – Drug Pipeline Therapeutic Assessment
This section of the bladder cancer report covers the analysis of bladder cancer drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s bladder cancer therapeutic assessment report covers 50+ drug analyses based on the route of administration.
The bladder cancer report insights cover phase I, phase II, phase III, phase IV, and early phase drugs for bladder cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II trials cover major share of the total bladder cancer clinical trials conducted.
National Cancer Institute (NCI) is conducting a phase II study of the drug - sorafenib to sylate to assess the efficacy for the treatment of advanced or metastatic cancer of the urinary tract.
Bladder Cancer –Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under bladder cancer pipeline landscape include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of bladder cancer. According to EMR analysis , the parenteral route holds a significant market share-based route of administration.
Bladder Cancer Clinical Trials Analysis – Competitive Dynamics
The EMR bladder cancer pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in bladder cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs in the bladder cancer pipeline landscape. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.
AU-011 - Aura Bios ciences
Aura Biosciences’ AU-011 is under phase I clinical trial, intended to assess the safety and feasibility against bladder cancer utilizing intratumoral injection.
BI 6727, IV infusion - Boehring er Ingelheim
Boehringer Ingelheim is conducting a clinical trial to evaluate the safety and efficacy of drug BI 6727 in patients with metastatic or recurrent urothelial cancer or locally advanced after failure of first-line chemotherapy. It is presently under phase II trial.
LOXO-435 - Eli Lilly and Com pany
LOXO-435 by Eli Lilly and Company is currently under phase I clinical trial. The study is conducted to know the safety, efficacy, and side effects of bladder cancer drug candidate LOXO-435. The drug may be used to treat cancer of the cells that line the urinary system.
Atezolizumab - Hoffmann-La Roche
The study is being conducted to evaluate the effects of atezolizumab treatment in participants with metastatic urothelial bladder or locally advanced.
Key Questions Answered in the Bladder Cancer – Pipeline Assessment Report
Global Bladder Cancer Treatment Market
Global Bladder Scanner Market
Overactive Bladder Market
Global Cancer Immunotherapy Market
Report Coverage
Bladder Cancer Report by Expert Market Research gives comprehensive insights on the bladder cancer drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The report includes an analysis of over 100 pipeline drugs and 50+ companies . Moreover, the bladder cancer pipeline analysis based on efficacy and safety measures outcomes published for the trials will be covered including their adverse effects in bladder cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing bladder cancer pipeline development activities are covered. Additionally, bladder cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Bladder Cancer Drug Pipeline Outlook
Bladder cancer occurs when there is an uncontrollable growth of cells in the bladder lining. Initially these cancerous cells affect the normal functions of bladder and later spread to surrounding areas. Bladder cancer is of two types – non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Non-muscle-invasive bladder cancer is considered early stage and represents about 70-75% of all diagnoses while muscle-invasive bladder cancer is considered as an advanced stage and represents 25-30% of diagnoses. Bladder cancer is the fourth most common cancer in men.
The symptoms of bladder cancer include blood in the urine (hematuria), which may lead to bright red urine, painful and frequent urge to urinate, as well as back pain among others. The bladder cancer treatment options for bladder cancer depend on factors such as the grade and stage of the cancer. It includes chemotherapy in the bladder, chemotherapy for the whole body, immunotherapy , targeted therapy, radiation therapy and surgery. The approaches for bladder cancer surgery include transurethral resection of bladder tumor (TURBT), cystectomy, neobladder reconstruction, and continent urinary reservoir among others.
The ongoing research on clinical trials aims to identify efficient therapeutic targets, development of novel therapies which are emerging as promising treatment alternatives for bladder cancer.
For instance, in 2023, the U.S. FDA approved a two-drug combination of pembrolizumab (EV/pemb ro) and enfortumab vedotin to treat metastatic urothelial bladder cancer. The results of clinical trial showed that EV/pembro was better than cisplatin-based combination chemotherapy as first-line treatment. The study results also highlighted a reduction of 55% in disease progression compared to cisplatin-based chemotherapy treatment.
Mayo Clinic is conducting another trial for a bladder cancer emerging drug and is under phase III. The study is being conducted to assess the efficacy of immunotherapy for treatment-resistant non-muscle-invasive bladder cancer.
The bladder cancer report assessment covers the pathophysiology and epidemiology of bladder cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for the treatment of bladder cancer in detail.
Bladder Cancer – Drug Pipeline Therapeutic Assessment
This section of the bladder cancer report covers the analysis of bladder cancer drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase III and Phase IV)
- Mid-Stage Products (Phase II)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s bladder cancer therapeutic assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The bladder cancer report insights cover phase I, phase II, phase III, phase IV, and early phase drugs for bladder cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II trials cover major share of the total bladder cancer clinical trials conducted.
National Cancer Institute (NCI) is conducting a phase II study of the drug - sorafenib to sylate to assess the efficacy for the treatment of advanced or metastatic cancer of the urinary tract.
Bladder Cancer –Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under bladder cancer pipeline landscape include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of bladder cancer. According to EMR analysis , the parenteral route holds a significant market share-based route of administration.
Bladder Cancer Clinical Trials Analysis – Competitive Dynamics
The EMR bladder cancer pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in bladder cancer clinical trials:
- Endo Pharmaceuticals
- Fidia Farmaceutici s.p.a.
- TScan Therapeutics, Inc.
- Bristol-Myers Squibb
- AstraZeneca
- BioNTech US Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Boehringer Ingelheim
- Pfizer, Inc.
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs in the bladder cancer pipeline landscape. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.
AU-011 - Aura Bios ciences
Aura Biosciences’ AU-011 is under phase I clinical trial, intended to assess the safety and feasibility against bladder cancer utilizing intratumoral injection.
BI 6727, IV infusion - Boehring er Ingelheim
Boehringer Ingelheim is conducting a clinical trial to evaluate the safety and efficacy of drug BI 6727 in patients with metastatic or recurrent urothelial cancer or locally advanced after failure of first-line chemotherapy. It is presently under phase II trial.
LOXO-435 - Eli Lilly and Com pany
LOXO-435 by Eli Lilly and Company is currently under phase I clinical trial. The study is conducted to know the safety, efficacy, and side effects of bladder cancer drug candidate LOXO-435. The drug may be used to treat cancer of the cells that line the urinary system.
Atezolizumab - Hoffmann-La Roche
The study is being conducted to evaluate the effects of atezolizumab treatment in participants with metastatic urothelial bladder or locally advanced.
Key Questions Answered in the Bladder Cancer – Pipeline Assessment Report
- What is the current landscape of bladder cancer pipeline drugs?
- Which companies/institutions are developing bladder cancer therapeutic drugs?
- How many phase II drugs are currently present in bladder cancer pipeline drugs?
- Which company is leading the bladder cancer pipeline development activities?
- What is the current bladder cancer commercial assessment?
- What are the opportunities and challenges present in the bladder cancer drug pipeline landscape?
- What is the efficacy and safety profile of bladder cancer pipeline drugs?
- Which companies/institutions are involved in bladder cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in bladder cancer?
Global Bladder Cancer Treatment Market
Global Bladder Scanner Market
Overactive Bladder Market
Global Cancer Immunotherapy Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Bladder Cancer
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Bladder Cancer
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Bladder Cancer: Epidemiology Snapshot
- 5.1 Bladder Cancer Incidence by Key Markets
- 5.2 Bladder Cancer– Patients Seeking Treatment in Key Markets
- 6 Bladder Cancer: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Bladder Cancer: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Bladder Cancer, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Bladder Cancer Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Bladder Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 TAR-200
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Gemcitabine
- 10.2.3 Pembrolizumab
- 10.2.4 Nivolumab
- 10.2.5 Other Drug
- 11 Bladder Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Cabazitaxel
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Nivolumab
- 11.2.3 Oncofid-P-B
- 11.2.4 Durvalumab
- 11.2.5 Other Drugs
- 12 Bladder Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Atezolizumab
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Cabazitaxel
- 12.2.3 VAX014
- 12.2.4 Other Drugs
- 13 Bladder Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 FL-101
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Abemaciclib
- 13.2.3 re-TURBT
- 13.2.4 18F-fluciclovine
- 13.2.5 Other Drugs
- 14 Bladder Cancer, Key Drug Pipeline Companies
- 14.1 Endo Pharmaceuticals
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Fidia Farmaceutici s.p.a.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 TScan Therapeutics, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Bristol-Myers Squibb
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 AstraZeneca
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 BioNTech US Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Eli Lilly and Company
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Development
- 14.8 Hoffmann-La Roche
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Development
- 14.9 Boehringer Ingelheim
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Development
- 14.10 Pfizer, Inc.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
